CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Results from the phase 1b CodeBreak 100/1 trial show that administering the novel KRAS
inhibitor sotorasib alone prior to combining it with an immune checkpoint inhibitor led to
lower rates of grade 3-4 treatment-related adverse events compared with beginning
administration of the treatments concurrently.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
